Novartis AG(us:NVS)
109.61
-1.68%
Updated on 2025-04-02
Open:112.48
Close:109.61
High:112.50
Low:109.39
Prev Close:111.48
Volume:1.95M
Turnover:215.74M
Turnover Ratio:0.10%
Shares:1.98B
MarketCap:216.49B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 62 | 909746 | 0.04% | 7 | 13 | 22 |
| 2024-03-31 | 1298 | 139674550 | 6.84% | 87 | 420 | 535 |
| 2023-12-31 | 1294 | 140275312 | 6.86% | 127 | 389 | 507 |
| 2023-09-30 | 1348 | 148156805 | 7.20% | 89 | 349 | 624 |
| 2023-06-30 | 1354 | 206592804 | 9.99% | 142 | 355 | 579 |
| 2023-03-31 | 1206 | 170942164 | 8.15% | 81 | 343 | 560 |
| 2022-12-31 | 1212 | 170990696 | 8.06% | 158 | 296 | 549 |
| 2022-09-30 | 1144 | 179282301 | 8.33% | 56 | 314 | 538 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Dodge & Cox | 12236526 | 0.60% | -117459 | -0.95% |
| 2024-06-30 | Primecap Management Co/Ca/ | 12179345 | 0.60% | -238410 | -1.92% |
| 2024-06-30 | Morgan Stanley | 7416679 | 0.37% | 158298 | 2.18% |
| 2024-06-30 | Dimensional Fund Advisors Lp | 7407692 | 0.37% | 1389610 | 23.09% |
| 2024-06-30 | Loomis Sayles & Co L P | 5945383 | 0.29% | 27411 | 0.46% |
| 2024-06-30 | Franklin Resources Inc | 5339490 | 0.26% | -360299 | -6.32% |
| 2024-06-30 | Bank Of America Corp /De/ | 4845053 | 0.24% | -43140 | -0.88% |
| 2024-06-30 | Wellington Management Group Llp | 4384650 | 0.22% | -204700 | -4.46% |
| 2024-06-30 | Goldman Sachs Group Inc | 3081076 | 0.15% | 21715 | 0.71% |
| 2024-06-30 | Cullen Capital Management, Llc | 2870381 | 0.14% | -54043 | -1.85% |
About
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Address:Lichtstrasse 35
Website:http://www.novartis.com
Market Movers